List of Accepted Abstracts
Shortlisted Adult Abstract Oral Presentation
Watch these presentation on Day 1 - 11 October 2024 during Oral Abstract 1 Session
DEK-NUP214 Monitoring of Acute Myeloid Leukemia before and after Allogeneic Haematopoietic Stem Cell Transplantation: A Report from the Trophy Study Group
Dr Shuang Fan, Peking University, China
Efficacy and Toxicity For CD7 Chimeric Antigen Receptor T-cell Therapy In Patients with Relapsed/Refractory T-cell Lymphoma
Dr Fan Yang, Beijing Gobroad Hospital, China
Implementation of Use of Peripherally Inserted Central Catheter (PICC) for the Administration of Peripheral Blood Stem Cells (PBSC) in all Patients Receiving Hematopoietic Stem Cell Transplantation (HSCT): A Quality and Safety Improvement Project by the NUHS HSCT Program (Final Analysis)
Mr Chia Kwee Cheng, National Cancer Institute of Singapore, Singapore
Efficacy of Modified Melphalan and Busulfan-based Conditioning Regimen for ASCT in Patients with Low- or Intermediate-risk AML
Ms Zhang Xiaoyu, National Clinical Research Center for Blood Diseases, China
Bifidobacterium Quadruple Viable Tablets Combined with Bacillus Coagulans Tablets for Graft-versus-host Disease Prophylaxis in Allogenic Hematopoietic Stem Cell Transplantation
Ms Ruowen Wei, Tongji Medical School, China
Feasibility and Safety of Prophylactic CD45RA-Depleted Donor Lymphocyte Infusion in Recipients of TCRαβ+ Depleted Haploidentical Grafts
Dr Quek Kim Siang Jeffrey, Singapore General Hospital, Singapore
Optimization of Pre-transplant Conditioning for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia: Interim Phase 2 Results of TBI-augmented Reduced Toxicity Regimen Incorporating ATG/PTCy
Mr Jaehyun Ahn, College of Medicine, The Catholic University of Korea, South Korea
Shortlisted Paediatric Abstract Oral Presentation
Watch these presentation on Day 1 - 11 October 2024 during Oral Abstract 2 Session
Comparation of Fresh and Cryopreserved Allogenic Hematopoietic Stem Cell Transplantation Outcome from Unrelated Donors in Pediatric Patients: A Single Center Experience
Dr Leila Jafari, Gene, Cell And Tissue Research Institute, Tehran University Of Medical Science, Iran
Lineage-Specific Chimerism Monitoring Using Flow Cytometry with Anti HLA-antibodies in Haploidentical Haematopoietic Stem Cell Transplantation
Dr Chan Yau Ki Wilson, Hong Kong Children's Hospital, Hong Kong
The Impact of Plasma Exchange for Donor Specific Antibodies in Children Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Thalassemia Major – What should Nurses Know
Mrs Jerlin Grace, Apollo Cancer Centres, India
Pre-Emptive CMV-EQBV Bi-Specific Cytotoxicity T Cell Therapy in Children Undergone Allogeneic Hematopoietic Stem Cell Transplantation – A Perspective Study
Dr Xindan Lian, Shenzhen Children's Hospital, China
Infusion of ABO Incompatible Stem Cells – The Role of Nursing Team
Ms Jenifer R, Apollo Cancer Centres, India
TCRαβ-Depleted Haplo-HSCT Following CAR-T Therapy Improves GVHD-free/Relapse-free Survival in Pediatric R/R-ALL
Dr Huaying Liu, Nanfang-Chunfu Children's Institute of Hematology and Oncology, China
Twenty-Year Outcome Study on Hematopoietic Stem Cell Transplantation in Childhood Acute Lymphoblastic Leukemia: A Single-centre Study from India
Dr Anupama Nair, Apollo Cancer Centres, India
Twenty-Year Outcome Study on Hematopoietic Stem Cell Transplantation in Childhood Acute Myeloid Leukemia: A Single-Center Study from India
Dr Aarthi N, Apollo Cancer Centres, India
We are grateful to have received many abstract submissions and in order to showcase the excellent work by various authors, each shortlisted poster abstract (labelled with asterisk *) will be showcased physically for both congress days (11 & 12 Oct 2024) while each of the accepted poster abstract will be showcased physically for either 1 of the congress days. You may check out the poster abstracts in the Poster Abstract Room at Level 2 Whitespace and approach the authors physically to learn more during their respective Q&A Standby time.
Onsite attendees may view the poster presentations of the shortlisted poster abstracts on Day 1 - 11 October 2024 during the Poster Viewing & Judging Session.
Virtual attendees may view the poster abstract via the Abstract Hall of the Virtual Congress Platform.
Poster Abstract Q&A Standby Date Time: 11 Oct (Fri) 10.40am - 10.55am
Adult Abstracts
Impact of Covid-19 Pandemic on Blood Supply: A Comparative Cross-sectional Study of the Pre-pandemic and Pandemic Era
Dr Johnmerson Yap, Southern Philippines Medical Center, Philippines
Four Tandem Autologous Stem Cell Transplantation for Gestational Trophoblastic Neoplasm Refractory to Multiple Lines of Therapy – A Dernier Ressort
Dr Jayachandran Perumal Kalaiyarasi, Cancer Institute (WIA), India
Cost-Effectiveness and Budget Impact Analyses of Axicabtagene Ciloleucel as Second-line Therapy in Patients with Large B-cell Lymphoma in Singapore
Dr Francesca Lorraine Lim, Singapore General Hospital, Singapore
Factors Contributing to Challenges in Hematopoietic Stem Cell Transplantation Nursing and Considerations for Necessary Nursing Education
Ms Satoko Nishio, Aichi Medical University, Japan
Impact of Post-transplant Cyclophosphamide (PTCy), Anti-thymocyte Globulin Combined with PTCy, PTCy Dose, and HLA Disparity on Development of Infectious Complications and Infection-related Mortality
Dr Hirohisa Nakamae, Osaka Metropolitan University Graduate School of Medicine, Japan
Secondary Salvage Allogeneic Hematopoietic Stem Cell Transplantation（allo-HSCT） in Relapsed and Refractory AML
Dr Song Yanzhi, Beijing Gobroad Boren Hospital, China
Nurses Attitude towards Caring for Patients during End of Life at a Tertiary Cancer Care Centre: A Cross Sectional Survey
Mrs Usha Vikas Gawade, Actrec Kharghar TMC, India
Brentuximab Vedotin Plus Cisplatin, Cytarabine, and Dexamethasone in Patients with Relapsed or Refractory Hodgkin’s Lymphoma who are Eligible for Transplant
Prof Jun Ho Yi, Chung-Ang University, South Korea
Combination of Low Dose Anti-Thymocyte Globulin (ATG) and Reduced Dose Post Transplant Cyclophosphamide (PTCy), for Haploidentical Stem Cell Transplant in Acute Leukemia : A Single Center Retrospective Study
Dr Wong Tien Gen, Hospital Ampang, Malaysia
Pilot Study of Efficacy of Romiplostim in Post-Transplant Settings to Hasten Platelet Recovery
Dr Madhupriya B, St Johns Medical College Hospital, India
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation with Teniposide Containing Conditioning in Patients of Hematologic Malignancies with Extramedullary Diseases
Ms Wang Rui, Beijing Gobroad Boren Hospital, China
EASIX Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
Ms Shipei Xiang, The First Affiliated Hospital, Zhejiang University School of Medicine, China
Efficacy of Bispecific Antibodies and Autologous Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Diffuse Large B-cell Lymphoma: A Systematic Review and Meta-analysis
Dr Relly Kurniawan, Diponegoro University, Indonesia
Perception of Patients in Relation to Her/His Experiences in Bone Marrow Transplant Unit (BMTU)
Mrs Jayakumari J, CMC, Vellore, Tamilnadu, India
Pyoderma Gangrenosum Complicated by Non-Pseudomonal Ecthyma Gangrenosum Caused by Escherichia Coli in a Patient with Myelodysplastic Syndrome Treated with Intravenous Antibiotics and Allogeneic Hematopoietic Stem Cell Transplantation
Dr Christine Faith Vasquez Tan, National Kidney and Transplant Institute, Philippines
*Haplo-identical Hematopoietic Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndrome in Korea
Prof Seongkyu Park, Soonchunhyang University Hospital, South Korea
A Formula Using Day 4 Parameters to Predict Next-day Peripheral Blood Stem Cell Yield in Healthy Haematopoietic Stem Cell Donors
Dr Jing Yuan Tan, Singapore General Hospital, Singapore
*Allogeneic Peripheral Blood Stem Cell Transplantation for Myeloid Sarcoma: A Single-center Experience
Dr Wenbin Cao, State Key Laboratory of Experimental Haematology, China
Paediatric Abstracts
Comparative Outcomes of Related and Unrelated Donor Transplants for Beta-thalassemia Major: A Single Centre Experience
Dr Manasi Gupta, Christian Medical College, Ludhiana, India
Lymphocyte Recovery and the Risk of Viral Reactivation in Children Post Allogeneic Hematopoietic Stem Cell Transplantation: Single Centre Experience
Dr Archana Melavarige Venkatagiri, Kasturba Medical College, Manipal Academy Of Higher Education, India
A Successful Two Case Childhood Beta-Thalassemia Major in Indonesia’s First Pediatric Hematopoietic Stem Cell Transplantation Unit: A Case Report
Ms Cresentia Irene Iskandar, Tzu Chi Hospital, Indonesia
*Generic Health-related Quality of Life Among Patients who Received Hematopoietic Stem Cell Transplantation during Childhood: A Meta-analysis of Observational Studies
Dr Shohei Nakajima, Teikyo University, Japan
*Safety and Efficacy of Sodium Nitroprusside Infusion for Hypertensive Emergencies in Children Undergoing Hematopoietic Stem Cell Transplantation – Old Wine in a New Bottle
Ms R Nithiyalakshmi, Apollo Cancer Centres, India
Poster Abstract Q&A Standby Date Time: 11 Oct (Fri) 12.40pm - 12.55pm
Adult Abstracts
Letermovir Primary Prophylaxis in Preventing Cytomegalovirus (CMV) Reactivation in Ex-vivo TCRαβ-Depleted Haploidentical Allogeneic Haematopoietic Cell Transplantation with Memory T Cell Add-Back
Ms Boo Ao Ran, National University Hospital, Singapore
8 Years of Unrelated Hematopoietic Cells Searching Program Between Blood Transfusion Hematology Hospital - Vietnam and Buddhist Tzu Chi Stem Cells Center – Taiwan
Mr Huynh Van Minh, Blood Transfusion Hematology Hospital, Vietnam
Safety and Efficacy of Generic Propylene Glycol Free Melphalan as Conditioning Chemotherapy for Autologous Stem Cell Transplant in Multiple Myeloma – A Single Center Experience from a Tertiary Care Hospital in Southern India
Dr Sudeep Vaniyath, Aster Malabar Institute Of Medical Sciences, India
Assessment of Patient Reported Symptom Burden and Impact on Daily Activities in Graft-versus-host Disease Patients
Mrs Sumaina KM, Tata Memorial Centre,Actrec, India
Nursing Experience of Acute Lymphoblastic Leukemia Receiving CAR-T Cell Therapy with Cytokine Release Syndrome
Ms Fang-Yu Liu, National Taiwan University Hospital, Taiwan
*Reducing Waiting Time for Therapeutic Plasma Exchange Procedure for Patients in Specialized Care Units: A Quality Improvement Project
Ms Nurasyikin Binte Mohamed Ishak, National University Cancer Institute, Singapore
Low-dose CD22 Monoclonal Antibody Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for Acute B Lymphoblastic Leukemia in non-remission or Minimal Residual Disease Positive after CD19 or CD22 CART-cell Therapy
Dr Song Yanzhi, Beijing Gobroad Boren Hospital, China
Incidence, Risk Factors and Clinical Consequences of Oral Mucositis in Hematopoietic Stem Cell Transplant (HSCT) Recipients
Mdm Hayati Binti Hussien, Hospital Pulau Pinang, Malaysia
Outcomes of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin Lymphoma Using Reduced Intensity Conditioning Regimens
Dr Suchita Shinde, Tata Medical Centre, Kolkata, India
Growth Differentiation Factor 15 (GDF-15) Levels in Patients with Transfusion-Dependent Thalassemia
Dr Afshan Sumera, University Of Central Lancashire, United Kingdom
Current Trends and Outcomes of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma in Mongolia
Dr Altanshagai Boldbaatar, The First Central Hospital of Mongolia, Mongolia
Real-World Data of Defibrotide for Treatment of Adult Patients who Developed Severe Hepatic VOD/SOS after Allogeneic Hematopoietic Cell Transplantation
Prof Jae Ho Yoon, Catholic Hematology Hospital, Seoul St. Mary's Hospital, The Catholic University of Korea, South Korea
*A Prospective, Single-arm Clinical Trial of Prevention of Severe Acute Graft-versus-host Disease after Adult Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation Using- a Machine Learning Model - The daGOAT Model
Dr Yigeng Cao, Institute Of Hematology & Blood Diseases Hospital, China
*Modified GIAC Strategy for Haploidentical BMT: A Preliminary Experience from IRCH, AIIMS
Dr Ranjit Kumar Sahoo, Aiims, New Delhi, India
Paediatric Abstracts
Use of Peripherally Inserted Central Venous Catheters (PICCs) in Children Receiving Autologous or Allogenic Stem-cell Transplantation and Chemotherapy
Ms Sabrina Alberti, Children's Hospital, Asst Spedali Civili Di Brescia, Italy
Establishment of the First Government-funded Paediatric Allogeneic Stem Cell Transplant Unit in Sri Lanka
Dr Shanika Vitharana, Lady Ridgeway Hospital for Children, Sri Lanka
Barriers to Care of Pediatric Hematopoietic Stem Cell Transplantation in a Tertiary Government-run Hospital in the State of Karnataka, India
Dr Vasundhara Kailasnath, Kidwai Memorial Institute of Oncology, India
*Durable Remission Achieved in Pediatric Patients with TCF3-HLF Positive R/R B-ALL by Dual CD19 and CD22-Targeted CAR-T Therapy
Dr Xinyu Wan, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, China
*Treosulfan, Thiotepa, Fludarabine Based Reduced Toxicity Conditioning Regimen in Children with High Risk Thalassemia Major - Report from a Tertiary Care Center in India
Dr Ravi Joshi, Mazumdar Shaw Medical Center Narayana Health City, India
Poster Abstract Q&A Standby Date Time: 11 Oct (Fri) 3.40pm - 3.55pm
Adult Abstracts
Development of Leaflets for Patient Education on Return to Work after Allogeneic Hematopoietic Cell Transplantation
Dr Saiko Kurosawa, Ina Central Hospital, Japan
Desensitisation Treatment For HLA-Donor Specific Antibodies In Ex-vivo T Cell Depleted Haploidentical Allogeneic Haematopoietic Stem Cell Transplantation – A Multi-centre Retrospective Study in Singapore
Dr Christopher Sw Tham, Singapore General Hospital, Singapore
Development and Validation of a Liquid Chromatography Tandem Mass Spectrometry-based Assay to Facilitate Busulfan Therapeutic Drug Monitoring in Adult Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation Treatment
Dr Ho Ying Shi, Singapore General Hospital, Singapore
Long-term Outcome of the Second Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies with Reduced Toxicity Conditioning and Donor Change
Ms Wang Rui, Beijing Gobroad Boren Hospital, China
Incidence and Predictive Factors for the Development of Adverse Reactions during Peripheral Blood Stem Cells Apheresis
Ms Rudchanu Baosingsuay, Phramongkutklao Hospital, Thailand
Transplanter’s Agony: A Case Series of Melphalan-associated Encephalopathy Following Conditioning Chemotherapy for Plasma Cell Dyscrasia
Dr Suchita Shinde, Tata Medical Center, Kolkata, India
Haploidentical Peripheral Blood Stem Cell Transplant with Fludarabine – Myeloablative Total Body Irradiation (TBI) as Conditioning Regimen with Post-Transplant Cyclophosphamide (PTCy) – A Single Centre Real World Experience
Dr Jayachandran Perumal Kalaiyarasi, Cancer Institute (WIA), India
A Retrospective Multi-centre Analysis of the Efficacy and Tolerability of ASCT for the Treatment of PCNSL
Dr Huirong Han, National University Cancer Institute Singapore, Singapore
Poor Graft Function Following Autologous Stem Cell Transplant: A Retrospective Review
Dr Wong Tien Gen, Hospital Ampang, Malaysia
Evaluation of WBC and Neutrophils Fluctuations in Adult Intensive Care Unit Patients without Steroid Or G-CSF Treatment: A Single Center Study in Korea
Prof Hee-Jeong Youk, Kangwon National University, South Korea
*The Outcome of CAR-T Therapy for Central Nervous System Lymphoma Following Failed Autologous Hematopoietic Stem Cell Transplantation
Dr Fan Yang, Beijing Gobroad Hospital, China
Nursing Experience of a Severe AML Patient with Secondary HSCT Skin Infection Caused by Fusarium
Ms Shuyue Xu, Beijing Gobroad Boren Hospital, China
Quality of Life (QoL) in Patients with Graft Versus Host Disease (GVHD) Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT), Department of Hematology, CMC, Vellore
Mrs Joyce Beulah, CMC, Vellore, Tamilnadu, India, India
Maintenance Therapy with Brentuximab after an Allogeneic Transplant for Relapsed Hodgkin’s Lymphoma Post Autologous Transplant
Dr Kevin, St Luke's Medical Center - Global City, Philippines
Optimization for Stem Cell Transplant through a Patient Centered Care (PCC) Multidisciplinary Team (MDT) Prehabilitation Approach: Case Report of a Multiple Myeloma Patient with Paraplegia from Spinal Cord Disease
Ms Lee Zhao Yuan, Singapore General Hospital, Singapore
*Chemical Stability and Sterility Of Plerifor® (Plerixafor) Solution for Injection after Opening Single-Use Vial
Ms Utairat Meeudompong, Siriraj Hospital, Mahidol University, Thailand
Paediatric Abstracts
Vedolizumab in Steroid Refractory Acute Gastrointestinal Graft-versus-host Disease in Children
Dr Anitha Veera, Meenakshi Mission Hospital And Research Centre, India
*Outcomes of 1-day Non-myeloablative Salvage Regimen for Paediatric Patients with Graft Failure Following T-Cell Depleted Haploidentical Haematopoietic Stem Cell Transplantation in Hong Kong
Dr Chan Yau Ki Wilson, Hong Kong Children'S Hospital, Hong Kong
Therapeutic Drug Monitoring of Busulfan as a Determinant of Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Stem Cell Transplantation
Mr Issanun Hunnuan, Faculty Of Medicine Ramathibodi Hospital, Mahidol University, Thailand
*Treosulfan Associated Knock Knees in Children Post Hematopoietic Stem Cell Transplantation – Report from a 15 Year Follow Up Study
Dr Anupama Nair, Apollo Cancer Centres, India
Poster Abstract Q&A Standby Date Time: 12 Oct (Sat) 10.10am - 10.25am
Adult Abstracts
Asciminib, Ponatinib, and Prednisone for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia
Dr Kevin Sese, St. Luke's Medical Center - Global City, Philippines
Examine the Prognostic Value of Geriatric Features in Allogeneic Hematopoietic Stem Cell Transplant Recipients Aged over 60 Years
Dr Lawrence Ng Cheng Kiat, Singapore General Hospital, Singapore
Subcutaneous Daratumumab in the Treatment of Pure Red-cell Aplasia Post ABO-mismatched Allogenic Haematopoietic Stem Cell Transplant: A Case Report
Dr Nicole-Ann Lim, Singapore General Hospital, Singapore
Comparative Efficacy and Safety of Lenograstim Versus Filgrastim for Hematopoietic Stem Cell Mobilization in Autologous Hematopoietic Stem Cell Transplantation: A Systematic Review
Dr Vina Yunarvika, Rsup Dr. Kariadi Semarang, Indonesia
Favourable Outcomes of Allogeneic Stem Cell Transplants in Chronic Myeloid Leukaemia: Data from a Tertiary Care Cancer Centre in India
Dr Shouriyo Ghosh, Tata Medical Center, India
Efficacy and Safety of Blinatumomab as Maintenance Therapy in Patients with High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation
Ms Tingting Zhang, Institute of Hematology and Blood Diseases Hospital, China
Etiology of Diarrhea in Patients Undergoing Colonoscopic Biopsies Post Allogeneic Hematopoietic Stem Cell Transplant for Suspected Acute Gut Graft-versus-host Disease
Dr Sachin Punatar, Actrec, Tata Memorial Centre, India
42 Patients with Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation Undergoing Continuous Bladder Irrigation Nursing Care
Mrs Huijuan Zhang, Blood Diseases Hospital, Chinese Academy of Medical Sciences, China
GvHD Prophylaxis with PTCy after Matched Sibling Allogeneic Stem Cell Transplant, Case Series from Evercare Hospital Dhaka, Bangladesh
Dr Quazi Smita Haq, Evercare Hospital Dhaka, Bangladesh
Gut Microbiota Profiling in Allogenic Hematopoietic Stem Cell Transplantation and Prediction of Acute Gastrointestinal GVHD from a Tertiary Care Centre in North India
Dr Md. Rizwan Athar, SGPGI, India
Comparison between Thiotepa-Treosulfan and Thiotepa-Busulfan Based Conditioning Regimes Prior to Allogeneic Haematopoetic Stem Cell Transplant in Adults with Haematological Malignancies
Dr Wong Kye Ling, Singapore General Hospital, Singapore
Second Primary Malignancies Post Autologous Stem-Cell Transplant in Multiple Myeloma from India – Knowing the Unknown
Dr Gourav Bain, Tata Memorial Centre, India
Study on Comprehensive Medical Evaluation of Unrelated Blood Stem Cell Donors Prior to Donation
Mr Chandrashekar R, DKMS BMST Foundation India, India
Paediatric Abstracts
The Outcome of Intravenous Mesenchymal Stem Cell Therapy against Chronic Graft-versus-host Disease of Pediatrics
Dr Rashin Mohseni, Gene, Cell & Tissue Research Institute, Iran
Five-year Study of Environmental Bacterial Sepsis in Children Undergoing Hematopoietic Stem Cell Transplantation
Mrs Jerlin Grace, Apollo Cancer Centres, India
Low Dose Post Transplant Cyclophosphamide as GVHD Prophylaxis for Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplants in Children
Dr Ravi Joshi, Mazumdar Shaw Medical Center Narayana Health City, India
Impact of Children Stress Level towards Quality of Life of Children with Acute Lymphoblastic Leukemia (ALL)
Dr Priscilla Diah Pratami, Sayang General Hospital, Cianjur, Indonesia
Poster Abstract Q&A Standby Date Time: 12 Oct (Sat) 12.10pm - 12.25pm
Adult Abstracts
Non-Hodgkin Lymphoma Evolving into Lymphoblastic Lymphoma in a 40-year-old Woman: A Rare Case with Poor Prognosis
Mrs Ainun Basyiroh Lubis, Diponegoro University, Indonesia
Extramedullary Acute Myeloid Leukemia among Filipino Female Hematopoietic Stem Cell Transplant Patients: A Case Series
Dr Aldous Stephen Quimpo Gomez, St. Luke's Medical Center - Global City, Philippines
Donor-recipient Weight Ratio as a Predictor for Stem Cell Yield in Peripheral Blood Stem Cell Collection
Dr Cheong Chin Sum, Universiti Malaya, Malaysia
An Observational Study on the Variability of Nutritional Status and its Impact on Transplant Outcomes in Patients Undergoing Hematopoietic Stem Cell Transplant
Dr Manasi Gupta, Christian Medical College, Ludhiana, India
Molecular Profiling of an Acute Myeloid Leukaemia Transplantation Cohort in the Era of Next-generation Sequencing
Dr Ang Chieh Hwee, Singapore General Hospital, Singapore
Graft Rejection and Failure after Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplant among Patients in a Tertiary Hospital in the Philippines: A Case Series
Dr Micah Fiel Baliclic, St. Luke's Medical Center - Global City, Philippines
Bone Marrow Transplant in Relapsed Diffuse Large B-cell Lymphoma (DLBCL) at an Uncommon Site in a 50-Year-Old Woman
Dr Warigit Dri Atmoko, Dr Kariadi Hospital, Indonesia
Procalcitonin is Superior to CRP in Predicting Bacteraemia and Mortality in Neutropenic Fever in Patients with Haematological Malignancies
Dr Naveenvairamoorthy Dakshinamoorthy, Sir Ganga Ram Hospital, India
Flumatinib Maintenance after Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Dr Chen Liang, State Key Laboratory of Experimental Hematology, China
SingHealth Haematopioetic Stem Cell Transplant Course for Nurses
Mr Hwang Chung Cheng, Singapore General Hospital, Singapore
Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation In FLT3-ITD Mutated Acute Myeloid Leukemia Patients Treated with Gilteritinib
Dr Daehun Kwag, Seoul St.Mary's Hospital, South Korea
Paediatric Abstracts
Evaluation of The Prevalence and Risk Factors of Hemorrhagic Cystitis in Pediatric Immunodeficiency Patients Following Hematopoietic Stem Cell Transplantation
Dr Maryam Behfar, Gene, Cell And Tissue Research Institute, Tehran University Of Medical Science, Iran
Allogeneic Stem-cell Transplantation Following Chimeric Antigen Receptor T-cell For the Treatment of Relapsed/Refractory Hematologic Malignancy in Pediatrics and Young Adults: A Systematic Review and Meta-analysis of Clinical Studies
Dr Reganedgary Jonlean, Indonesia Tzu Chi Hospital, Indonesia
Partially Replacing the Post Transplant Cyclophsophamide with Bendamustin in Haploidentical Stem Cell Transplantation – in Children - Tertiary Care Experience
Dr Ranjit Kumar C.S, Sindhu Hospitals, India
Poster Abstract Q&A Standby Date Time: 12 Oct (Sat) 3.40pm - 3.55pm
Adult Abstracts
Fluorescence in situ Hybridization (FISH) Analysis on Bone Core Specimens Detects Disease Relapse in Myeloid Malignancies with Fibrosis
Dr Chu Lee Voon, Singapore General Hospital, Singapore
The Efficacy and Safety of Ixazomib for Multiple Myeloma: A Systematic Review
Mrs Ainun Basyiroh Lubis, Diponegoro University, Indonesia
Survival Analysis of Patients Given First Autologous Stem Cell Transplantation in Hematologic Malignancies: A Single Center 10 Years Experience
Dr Mila Astrilia, Faculty Of Medicine, Diponegoro University, Indonesia
In the Blink of an Eye - Bell’s Palsy as an Initial Presentation of CNS Relapse of T-Cell ALL – A Case Report
Dr Jasmine Clarisse Cheng, St Lukes Medical Center - Global City, Philippines
Donor Factors Affecting Outcomes of PTCy Based T Cell Replete Haploidentical Transplants: A Single Centre Experience from India
Dr Sachin Punatar, Actrec, Tata Memorial Centre, India
Korean Real-World Experience of Blinatumomab for 8 Years Regarding Predictive Factors including Lymphocyte Kinetics for Response and Survival Outcome in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
Dr Seonghan Lee, College Of Medicine, The Catholic University of Korea,, South Korea
Allogeneic Peripheral Blood Stem Cell Transplantation Outcomes Among Adult Filipino Patients with Myelofibrosis: A Case Series and Review of Literature
Dr Fredrich Marlou L. Nierra, St. Luke's Medical Center - Global City, Philippines
A 5-year Retrospective Analysis of the Use of Extracorporeal Photopheresis (ECP) via UVA-PIT in Treating Graft-versus-host Disease (GVHD) in Singapore General Hospital (SGH) Apheresis Unit
Ms Xie Gaoge, Singapore General Hospital, Singapore
A Single Centre Experience on Clinical Outcomes of Hematopoietic Stem Cell Transplant in Acute Myeloid Leukemia Patients
Dr Santhosh Subramanian, Manipal Hospitals, India
Unraveling Thrombocytopenia after Autologus Stem Cell Transplantation in Multiple Myeloma: A Case Report
Dr Ika Kartiyani, Kariadi Hospital, Indonesia
Paediatric Abstracts
Hematopoietic Stem Cell Transplantation (HSCT) for Hemoglobinopathies
Prof Amir Ali Hamidieh, Gene, Cell And Tissue Research Institute, Tehran University of Medical Science, Tehran, Iran, Iran
Hematopoietic Stem Cell Transplant as a Cure for Glucose 6 Phosphate Isomerase Deficiency in Siblings - Case Report from a Tertiary Care Centre in India
Dr Lakshmi T, Mazumdar Shaw Medical Centre, Bangalore, India
Outcome Analysis of High-risk Neuroblastoma Post Autologous Stem Cell Transplant in a Newly Set Pediatric Transplant Centre, Bengaluru, South India
Dr Vasundhara Kailasnath, Kidwai Memorial Institute of Oncology, India
Abstract Submission Deadline: 31 JULY 2024 (Closed)
You are invited to submit informative abstracts of up to 500 words (2800 characters) which would not include the title of the abstract, author affiliations and other headings like Aims, Methods, Results & Conclusions. The abstract may include a maximum of two charts or figures as Supporting Data (which will not be included in 500 words / 2800 characters limit).
Abstracts must be submitted according to guidelines given below. All abstracts must be submitted using the Abstract Submission Form.
ABSTRACT TITLE
Please write the title in Title Case (each main word has a capital letter). Do not use quotation marks.
e.g. The Results of the Research Case Study and Its Participants
AUTHORS & AFFILIATIONS
-
The full names (no initials) of all participating authors (including yourself) must be included on the abstract. Please do not include degrees or professional titles.
-
Author Affiliations – please include the name of your organization, the city, the state and the country.
ABSTRACT TEXT
Abstracts that merely state the results that will be presented will be subject to rejection. All abstracts are subject to review by the Scientific Committee and acceptance into the program is not guaranteed. The Committee suggests that the abstract follow the format outlined below:
-
Aims
-
Methods
-
Results
-
Conclusions
CONFLICT OF INTEREST STATEMENT
If the research described in the abstract was supported by a commercial company, you must indicate the company’s role in analysing the data or preparing the abstract.
One of the following must appear at the bottom of the abstract:
“No conflict of interest to disclose”.
“This research was supported by . The company had no role in analysing the data or preparing the abstract.”
“This research was supported by . The company inserts free text describing company role in data analysis or abstract preparation.”
This conflict-of-interest statement is mandatory for all abstracts submitted and will appear wherever the abstracts are published. For oral presentations, a sample slide will be available to presenters for disclosure of conflicts of interest to be displayed as the first or second slide of their presentation
ABSTRACT CATEGORIES
The abstracts must be submitted in one of the following categories:
-
Acute Leukemia
-
Lymphoma and Chronic Lymphocytic Leukemia
-
Multiple Myeloma
-
Myelodysplastic Syndromes
-
Myeloproliferative Neoplasm
-
Hemoglobinopathies, Primary Immune Deficiency, and Metabolic Disorders
-
Conditioning Regimens
-
Graft-versus-host Disease
-
Infectious and Non-infectious complications
-
Pediatric Transplantation
-
Cell and Gene Therapy
-
Quality of Life / Survivorship
-
Basic Science
-
Allied Health including Nursing, Pharmacology, and Laboratory Aspects
Submission of the abstract carries with it an obligation to present the accepted abstract in person or virtually without any change in scientific content during the allotted time in the above conference. Withdrawal of presentation should be intimated to the scientific committee on or before 31 AUGUST 2024, by writing to the conference Secretariat at
contact@annualmeeting.2024.apbmt.org.
If an author as the presenting author is not able to present the paper for the conference due to any reason, prior permission has to be obtained from the Program Committee regarding the change in the presenting author.
POSTER PRESENTATION GUIDELINES
-
Poster size & material: A0 (Portrait) Foamboard 5mm
-
Participants are kindly advised to bring their own posters, which will be displayed at the event.
-
The poster must contain the name of all authors and the author’s Institution or University
ABSTRACT SUBMISSION FORM (Closed)
Presenting Author's Particulars
Salutation*
Department*
Mailing Address*
Postal Code*
Contact Number*
Full Name*
Institution*
City & State / Province*
Country*
Email*
Abstract Information
Preferred Mode of Presentation*
(Subject to the Scientific Committee's decision)
Abstract category*
Type of Abstract*
Abstract Title*
Please write the title in Title Case (each main word has a capital letter). Do not use quotation marks.
e.g. The Results of the Research Case Study and Its Participants
Abstract Content*
Text length NOT to exceed 500 words. The text of the abstract should include section headings such as Aims, Methods, Results and Conclusions. The section headings should appear in bold.
Word Count: 0
Co-author(s)' Information
There is no co-author for this abstract.
Full Name*
Email*
Department*
Institution of Affiliation*
City & State / Province*
Country*
There is no co-author for this abstract.
More details are coming soon!
Powered by
